WASHINGTON, D.C., Oct. 16 /PRNewswire/ -- It's a fact -- many Americans
would rather "die" than go to the dentist. A recent study of dental attitudes
says nearly one in 10 people equate going to the dentist with fear of dying.
Researchers also found that about 50 percent of adults express some level of
anxiety when faced with a prospect of sitting in the dentist's chair,
according to the survey sponsored by Noven Pharmaceuticals, Inc.
Almost 80 percent of the 1,078 adult respondents said they would be more
willing to visit the dentist if there was a pain-free option available.
Dental phobics can relax. A new approach to reducing needle pain is now
available. DentiPatch(R) (lidocaine transoral delivery system), being
demonstrated at the American Dental Association (ADA) meeting in Washington,
D.C. (Oct. 18-22), offers safe localized numbing and may replace injections in
some procedures. DentiPatch(R), a small band-aid-like strip, is applied
directly onto the palate or gums and can be used for common soft-tissue dental
procedures such as scaling and root planing. The FDA has approved
DentiPatch(R) for marketing and is now available nationwide.
Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) is an industry leader in the
development and commercialization of advanced drug-delivery systems. For more
information on DentiPatch(R) and Noven Pharmaceuticals, Inc. visit our Web
site at http//www.dentipatch.com.
Forward looking statements contained herein are qualified by and subject
to the risks and uncertainties specified by Noven in its most recent periodic
filings with the Securities and Exchange Commission.
SOURCE Noven Pharmaceuticals, Inc.